Rafferty Asset Management, LLC Viridian Therapeutics, Inc.\De Transaction History
Rafferty Asset Management, LLC
- $28.9 Billion
- Q3 2024
A detailed history of Rafferty Asset Management, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 90,651 shares of VRDN stock, worth $1.76 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
90,651
Previous 144,975
37.47%
Holding current value
$1.76 Million
Previous $1.89 Million
9.33%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding VRDN
# of Institutions
180Shares Held
76.7MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$92.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$85.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$75.4 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$72.9 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$67 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $775M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...